← Leaderboards
Farshad Guirakhoo
Geovax, Inc.
$899,820
Attributed
$899,820
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $599.8K · FY2017–18$1M$750K$500K$250K$0
'17
'18
Funding mix
By agency
NIH$899,820 · 2
By mechanism
R43$600,000 · 1
R44$299,820 · 1
Top collaborators
No co-investigators on record.
Most similar at Geovax, Inc.
Same institution · by research overlap
- Arban Domi$593,623
- Sue Fen Kwa$276,690
Others in their field
Other Emerging Leaders on “Immunogenicity”
- Ted Ross · University Of Georgia$71,962,304
- Yunda Huang · Fred Hutchinson Cancer Center$54,671,444
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Julie Ake · National Institute Of Allergy And Infectious Diseases$50,742,120
- Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn$50,288,546
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$44,140,914
Research focus
ImmunogenicityNonhuman PrimateClinical TrialsImmune ResponseModified Vaccinia Virus AnkaraNeutralizing AntibodyCellsClinical ResearchDoseGeneticInfectionMediatingAfricaMouse ModelAntibody ResponseBiological ModelsAntigensClinical DevelopmentAnimalsCyclic GmpEbola VirusEfficacy TestingAntibodiesPreclinical Testing
Grant awards (3)
Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus$300,000
R43 · FY2018 · AI · contact PI
Construction and efficacy testing of novel recombinant vaccine designs for eliciting both broadly neutralizing antibodies and T cells against Lassa virus$299,820
R44 · FY2018 · AI · contact PI
Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus$300,000
R43 · FY2017 · AI · contact PI